Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoladex 10.8 mg vs 3.6 mg in Pre-menopausal ER+ Early Breast Cancer
NCT00303524Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2006
- Primary completion
- Aug 2007
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of goserelin in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Area Under the Curve (AUC) of Oestradiol (E2) Concentration at 24 weeks. Started Feb 2006; status: completed.
02
Drugs
goserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00303524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303524.